| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc. | 1.96B | 14.87 | 378.37 | 33.97% | 29.28% | 21.28% | 2.25% | 0.21 |
| ARGXargenx SE | 50.33B | 813.24 | 63.63 | 78.6% | 23.34% | 15.14% | 0.01 | |
| INVAInnoviva, Inc. | 1.48B | 19.76 | 54.89 | 15.54% | 32.78% | 12.61% | 12.75% | 0.65 |
| GLPGGalapagos N.V. | 2.24B | 34.03 | 30.38 | 14.99% | -151.94% | -15.16% | 0.00 | |
| PTGXProtagonist Therapeutics, Inc. | 5.3B | 84.75 | 20.04 | 6.24% | 21.94% | 7.11% | 3.45% | 0.02 |
| ALMSAlumis Inc. Common Stock | 2.84B | 24.17 | -2.33 | -11.08% | -63.71% | 0.12 | ||
| PHATPhathom Pharmaceuticals, Inc. | 1.17B | 14.98 | -2.83 | 80.01% | -186.53% | |||
| ORKAOruka Therapeutics, Inc. | 1.57B | 32.50 | -6.51 | -22.44% | 0.00 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 5.04M | 3.81M | 1.53M | 0 | 0 |
| Revenue Growth % | - | - | - | - | -0.24% | -0.6% | -1% | - |
| Cost of Goods Sold | 1.38M | 1.24M | 1.33M | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - |
| Gross Profit | -1.38M | -1.24M | -1.33M | 5.04M | 3.81M | 1.53M | 0 | 0 |
| Gross Margin % | - | - | - | 1% | 1% | 1% | - | - |
| Gross Profit Growth % | - | 0.11% | -0.08% | 4.79% | -0.24% | -0.6% | -1% | - |
| Operating Expenses | 29.33M | 36.95M | 43.63M | 58.26M | 73.02M | 87.32M | 127.06M | 136.1M |
| OpEx % of Revenue | - | - | - | 11.55% | 19.15% | 57.19% | - | - |
| Selling, General & Admin | 3.71M | 5.18M | 8.72M | 12.77M | 16.04M | 20.24M | 26.06M | 28.88M |
| SG&A % of Revenue | - | - | - | 2.53% | 4.21% | 13.25% | - | - |
| Research & Development | 25.62M | 31.77M | 34.91M | 45.48M | 56.98M | 67.08M | 101M | 107.22M |
| R&D % of Revenue | - | - | - | 9.02% | 14.94% | 43.93% | - | - |
| Other Operating Expenses | 216K | 800K | 1.29M | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -29.33M | -36.95M | -43.63M | -53.21M | -69.21M | -85.8M | -127.06M | -136.1M |
| Operating Margin % | - | - | - | -10.55% | -18.15% | -56.19% | - | - |
| Operating Income Growth % | - | -0.26% | -0.18% | -0.22% | -0.3% | -0.24% | -0.48% | -0.07% |
| EBITDA | -27.95M | -35.71M | -42.3M | -52.09M | -68.21M | -84.75M | -125.85M | -134.9M |
| EBITDA Margin % | - | - | - | -10.33% | -17.89% | -55.5% | - | - |
| EBITDA Growth % | - | -0.28% | -0.18% | -0.23% | -0.31% | -0.24% | -0.48% | -0.07% |
| D&A (Non-Cash Add-back) | 1.38M | 1.24M | 1.33M | 1.12M | 996K | 1.05M | 1.22M | 1.2M |
| EBIT | -29.33M | -36.95M | -43.63M | -53.21M | -69.21M | -85.8M | -127.06M | -136.1M |
| Net Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 216K | 800K | 1.29M | 1.31M | 5K | 1.96M | 10.26M | 6.24M |
| Pretax Income | -29.11M | -36.15M | -42.34M | -51.9M | -69.2M | -83.84M | -116.8M | -129.87M |
| Pretax Margin % | - | - | - | -10.29% | -18.15% | -54.9% | - | - |
| Income Tax | 0 | 0 | 660K | 990K | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1.02% | 1.02% | 1% | 1% | 1% | 1% |
| Net Income | -29.11M | -36.15M | -43M | -52.89M | -69.2M | -83.84M | -116.8M | -129.87M |
| Net Margin % | - | - | - | -10.49% | -18.15% | -54.9% | - | - |
| Net Income Growth % | - | -0.24% | -0.19% | -0.23% | -0.31% | -0.21% | -0.39% | -0.11% |
| Net Income (Continuing) | -29.11M | -36.15M | -43M | -52.89M | -69.2M | -83.84M | -116.8M | -129.87M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -10.95 | -13.59 | -15.75 | -17.53 | -20.21 | -20.61 | -24.37 | -25.49 |
| EPS Growth % | - | -0.24% | -0.16% | -0.11% | -0.15% | -0.02% | -0.18% | -0.05% |
| EPS (Basic) | -10.95 | -13.59 | -15.75 | -17.53 | -20.21 | -20.61 | -24.37 | -25.49 |
| Diluted Shares Outstanding | 2.66M | 2.66M | 2.73M | 3.02M | 3.42M | 4.07M | 4.79M | 5.1M |
| Basic Shares Outstanding | 2.66M | 2.66M | 2.73M | 3.02M | 3.42M | 4.07M | 4.79M | 5.1M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 48.24M | 65.06M | 80.51M | 115.6M | 192.97M | 252.69M | 161.78M | 235.24M |
| Cash & Short-Term Investments | 47.52M | 63.8M | 77.38M | 111.51M | 189.65M | 249.07M | 158.86M | 231.06M |
| Cash Only | 47.52M | 63.8M | 77.38M | 24.92M | 24.03M | 38.95M | 47.48M | 169.74M |
| Short-Term Investments | 0 | 0 | 0 | 86.59M | 165.63M | 210.12M | 111.38M | 61.32M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 0 | 0 | 4.09M | 3.32M | 3.63M | 2.92M | 4.18M |
| Total Non-Current Assets | 2.15M | 4.55M | 4.1M | 3.37M | 5.66M | 13.52M | 11.55M | 5.09M |
| Property, Plant & Equipment | 1.91M | 4.16M | 3.71M | 2.98M | 2.74M | 9.48M | 7.68M | 4.7M |
| Fixed Asset Turnover | - | - | - | 1.69x | 1.39x | 0.16x | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 605K | 598K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | -369K | -209K | 389K | 389K | 2.92M | 4.04M | 3.87M | 389K |
| Total Assets | 50.39M | 69.61M | 84.6M | 118.97M | 198.64M | 266.21M | 173.33M | 240.32M |
| Asset Turnover | - | - | - | 0.04x | 0.02x | 0.01x | - | - |
| Asset Growth % | - | 0.38% | 0.22% | 0.41% | 0.67% | 0.34% | -0.35% | 0.39% |
| Total Current Liabilities | 3.25M | 4.64M | 9.26M | 11.74M | 9.6M | 14.22M | 21.84M | 48.35M |
| Accounts Payable | 1.11M | 1.77M | 1.14M | 2.38M | 2M | 3.37M | 5.18M | 1.27M |
| Days Payables Outstanding | 291.68 | 522.57 | 313.68 | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 1000K | 1000K | 1000K | 0 | 0 | 0 |
| Other Current Liabilities | 650K | 586K | 2.25M | 2.3M | 2.93M | 4.65M | 7.91M | 6.78M |
| Current Ratio | 14.85x | 14.01x | 8.70x | 9.84x | 20.11x | 17.77x | 7.41x | 4.87x |
| Quick Ratio | 14.85x | 14.01x | 8.70x | 9.84x | 20.11x | 17.77x | 7.41x | 4.87x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 109.55M | 969K | 2.23M | 3.05M | 2.66M | 6.82M | 4.46M | 2.07M |
| Long-Term Debt | 108.64M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 6.82M | 4.46M | 2.07M |
| Deferred Tax Liabilities | -108.64M | -162.08M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 905K | 969K | 2.23M | 2.19M | 2.15M | 0 | 0 | 0 |
| Total Liabilities | 112.8M | 5.61M | 11.48M | 14.79M | 12.26M | 21.04M | 26.29M | 50.42M |
| Total Debt | 108.64M | 161.11M | 0 | 0 | 0 | 8.99M | 6.91M | 4.49M |
| Net Debt | 61.13M | 97.31M | -77.38M | -24.92M | -24.03M | -29.96M | -40.57M | -165.24M |
| Debt / Equity | - | 2.52x | - | - | - | 0.04x | 0.05x | 0.02x |
| Debt / EBITDA | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - |
| Total Equity | -62.41M | 64M | 73.12M | 104.18M | 186.38M | 245.17M | 147.03M | 189.9M |
| Equity Growth % | - | 2.03% | 0.14% | 0.42% | 0.79% | 0.32% | -0.4% | 0.29% |
| Book Value per Share | -23.46 | 24.06 | 26.79 | 34.53 | 54.44 | 60.27 | 30.68 | 37.27 |
| Total Shareholders' Equity | -62.41M | 64M | 73.12M | 104.18M | 186.38M | 245.17M | 147.03M | 189.9M |
| Common Stock | 1K | 2K | 2K | 2K | 3K | 3K | 3K | 13K |
| Retained Earnings | -82.81M | -118.95M | -161.95M | -214.84M | -284.05M | -367.88M | -484.68M | -614.55M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -3.77M | -4K | 20K | -177K | -206K | -26K | 103K | 50K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -27.12M | -32.95M | -35.47M | -40.49M | -61.03M | -70.77M | -97.05M | -83.3M |
| Operating CF Margin % | - | - | - | -8.03% | -16% | -46.35% | - | - |
| Operating CF Growth % | - | -0.21% | -0.08% | -0.14% | -0.51% | -0.16% | -0.37% | 0.14% |
| Net Income | -29.11M | -36.15M | -43M | -52.89M | -69.2M | -83.84M | -116.8M | -129.87M |
| Depreciation & Amortization | 1.38M | 1.24M | 1.33M | 1.12M | 996K | 1.05M | 3.55M | 1.2M |
| Stock-Based Compensation | 716K | 1.17M | 2.05M | 8.69M | 9.95M | 11.26M | 0 | 19.93M |
| Deferred Taxes | 15K | 17K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -9K | -14K | 9K | 248K | 1.53M | 2.09M | 10.7M | -477K |
| Working Capital Changes | -114K | 784K | 4.13M | 2.34M | -4.3M | -1.33M | 5.5M | 25.91M |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -80K | 1.48M | 736K | 2.39M | 933K | 3.71M | 7.33M | -8.46M |
| Cash from Investing | -1.12M | -3.5M | -843K | -87.44M | -81.35M | -45.49M | 104.13M | 52.7M |
| Capital Expenditures | -1.12M | -3.5M | -888K | -398K | -755K | -845K | -1.13M | -122K |
| CapEx % of Revenue | - | - | - | 0.08% | 0.2% | 0.55% | - | - |
| Acquisitions | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 45K | -87.04M | -80.59M | -44.65M | 0 | 0 |
| Cash from Financing | 30.1M | 52.73M | 49.9M | 75.46M | 141.48M | 131.18M | 1.45M | 152.85M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - |
| Other Financing | 30.1M | 52.73M | 0 | 1.85M | 2.02M | 1.39M | 0 | 845K |
| Net Change in Cash | - | - | - | - | - | - | - | - |
| Free Cash Flow | -28.25M | -36.45M | -36.36M | -40.89M | -61.78M | -71.62M | -98.17M | -83.42M |
| FCF Margin % | - | - | - | -8.11% | -16.2% | -46.9% | - | - |
| FCF Growth % | - | -0.29% | 0% | -0.12% | -0.51% | -0.16% | -0.37% | 0.15% |
| FCF per Share | -10.62 | -13.70 | -13.32 | -13.55 | -18.04 | -17.61 | -20.49 | -16.37 |
| FCF Conversion (FCF/Net Income) | 0.93x | 0.91x | 0.83x | 0.77x | 0.88x | 0.84x | 0.83x | 0.64x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 660K | 990K | 0 | 0 | 0 | 0 |
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -4538.23% | -62.71% | -59.66% | -47.64% | -38.85% | -59.56% | -77.09% |
| Return on Invested Capital (ROIC) | - | -34.63% | -41.67% | -106.43% | -42.97% | -34.09% | -59.25% | -155.69% |
| Gross Margin | - | - | - | 100% | 100% | 100% | - | - |
| Net Margin | - | - | - | -1049.03% | -1814.95% | -5490.37% | - | - |
| Debt / Equity | - | 2.52x | - | - | - | 0.04x | 0.05x | 0.02x |
| FCF Conversion | 0.93x | 0.91x | 0.83x | 0.77x | 0.88x | 0.84x | 0.83x | 0.64x |
| Revenue Growth | - | - | - | - | -24.38% | -59.95% | -100% | - |
RAPT Therapeutics, Inc. (RAPT) grew revenue by 0.0% over the past year. Growth has been modest.
RAPT Therapeutics, Inc. (RAPT) reported a net loss of $105.6M for fiscal year 2024.
RAPT Therapeutics, Inc. (RAPT) has a return on equity (ROE) of -77.1%. Negative ROE indicates the company is unprofitable.
RAPT Therapeutics, Inc. (RAPT) had negative free cash flow of $86.7M in fiscal year 2024, likely due to heavy capital investments.